Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.

Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS-CoV-2 vaccination in SCD is limited. We investigated anti-SARS-CoV-2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non-SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID-19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts. These findings suggest that patients with SCD achieve a similar antibody response following COVID-19 vaccination compared to the general population, with implications for optimal vaccination strategies for patients with SCD.

[1]  A. Jannot,et al.  Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease , 2022, British journal of haematology.

[2]  S. Stowell,et al.  The Development and Consequences of Red Blood Cell Alloimmunization , 2022, Annual review of pathology.

[3]  Asplenia and spleen hypofunction , 2022, Nature Reviews Disease Primers.

[4]  V. Gordeuk,et al.  COVID‐19 vaccination status and disease burden in patients with sickle cell disease , 2022, Blood.

[5]  C. Minniti,et al.  COVID19 vaccination in adults with sickle cell disease is not associated with increases in rates of pain crisis , 2022, Hematology.

[6]  M. Dhodapkar,et al.  Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Heemskerk,et al.  Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients , 2022, Blood Advances.

[8]  A. Anagnostopoulos,et al.  Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center , 2022, Journal of clinical medicine.

[9]  A. Hashem,et al.  Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies , 2022, Vaccines.

[10]  T. Duong,et al.  Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature , 2021, Blood Reviews.

[11]  B. Bell,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  S. Stowell,et al.  Comparison of Antibody Class-Specific SARS-CoV-2 Serologies for the Diagnosis of Acute COVID-19 , 2021, Journal of Clinical Microbiology.

[13]  O. Hermine,et al.  Innate immune cells, major protagonists of sickle cell disease pathophysiology , 2020, Haematologica.

[14]  J. Makani,et al.  Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses , 2016, American journal of hematology.